[1] Chen TC, Nakanuma Y, Zen Y et al. Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology 2001; 34: 651–8.
[2] Nakanuma Y, Curado M-P, Franceschi S, et al. Intrahepatic cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. World health organization classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010. p. 217–24.
[3] Albores-Saavedra J, Adsay NV, Crawford JM, et al. Carcinoma of the gallbladder and extrahepatic bile ducts. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. World health organization classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010. p. 266–73.
[4] Fukumura Y, Nakanuma Y, Kakuda Y, et al. Clinicopathological features of intraductal papillary neoplasms of the bile duct: a comparison with intraductal papillary mucinous neoplasm of the pancreas with reference to subtypes. Virchows Arch 2017; 471: 65-76.
[5] Nakanuma Y, Sato Y, Ojima H, et al. Clinicopathological characterization of so-called “cholangiocarcinoma with intraductal papillary growth” with respect to “intraductal papillary neoplasm of bile duct (IPNB)”. Int J Clin Exp Pathol 2014; 7: 3112-22.
[6] Nakanuma Y, Kakuda Y, Uesaka K. Characterization of intraductal papillary neoplasm of bile duct with respect to histopathologic similarities to pancreatic intraductal papillary mucinous neoplasm. Gut Liver 2019; 13: 617-27.
[7] Rocha FG, Lee H, Katabi N, et al. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology 2012; 56: 1352–60.
[8] Furukawa T, Klöppel G, Adsay NV, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 2005; 447: 794-9.
[9] Furukawa T, Hatori T, Fujita I, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut 2011; 60: 509-16,
[10] Nakanuma Y, Jang KT, Fukushima N, et al. A statement by the Japan-Korea expert pathologists for future clinicopathological and molecular analyses toward consensus building of intraductal papillary neoplasm of the bile duct through several opinions at the present stage. J Hepatobiliary Pancreat Sci 2018; 25: 181-7.
[11] Furukawa T, Klöppel G, Volkan Adsay N, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 2005; 447: 794–9
[12] Ikari N, Serizawa A, Furukawa T, et al. Near-comprehensive resequencing of cancer-associated genes in surgically resected metastatic liver tumors of gastric cancer. Am J Pathol 2019; 189: 784-96.
[13] Furukawa T, Fujisaki R, Yoshida Y, et al. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol 2005; 18: 1034-42.
[14] Sakamoto H, Kuboki Y, Hatori T, et al. Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol 2015; 28: 261- 7.
[15] Kuboki Y, Shimizu K, Hatori T, et al. Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas. Pancreas. 2015; 44: 227-35.
[16] Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat Protoc 2015;10: 1556-66.
[17] Zen Y, Fujii T, Itatsu K, et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 2006; 44: 1333-43.
[18] Tsai JH, Liau JY, Yuan CT, et al. RNF43 mutation frequently occurs with GNAS mutation and mucin hypersecretion in intraductal papillary neoplasms of the bile duct. Histopathology 2017; 70: 756-65.
[19] Yang CY, Huang WJ, Tsai JH, et al. Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct. Mod Pathol 2019; 32: 1637-45..
[20] Fujikura K, Akita M, Ajiki T, et al. Recurrent Mutations in APC and CTNNB1 and Activated Wnt/β-catenin signaling in intraductal papillary neoplasms of the bile duct: A whole exome sequencing study. Am J Surg Pathol 2018; 42: 1674-85.
[21] Springer S, Wang Y, Dal Molin M, et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology 2015; 149: 1501-10.
[22] Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov 2017; 7: 1116-35.
[23] Kuboki Y, Shimizu K, Hatori T, et al. Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas. Pancreas 2015; 44: 227-35.
[24] Sakamoto H, Kuboki Y, Hatori T, et al. Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol 2014; 28: 261- 7.
[25] Feldser DM, Kostova KK, Winslow MM, et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010; 468: 572-5.
[26] Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 2019; 575: 217-23.
[27] Matsumura N, Yamamoto M, Aruga A, et al. Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer 2002; 94: 1770-6.
[28] Park SY, Roh SJ, Kim YN, et al. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. Oncol Rep 2009; 22: 649-57.
[29] 米澤 傑, 東 美智代, 野元 三治, 他. ヒト腫瘍におけるムチンの発現と腫瘍の悪性度. 日本分子腫瘍マーカー研究会誌 2008;23: 5-6.
[30] 伊佐 勉, 狩俣 弘幸, 竹島 義隆, 他. 胆嚢癌における MUC1 および MUC2 ムチン発現の臨床的意義. 日本臨床外科学会雑誌 2001;62: 2621-6.
論文の公開元へ
